Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
S-TKIs permitted tailoring systemic treatment based on disease location, tumour volume and patient comorbidities, achieving satisfactory tolerance and outcomes in selected patients with an actionable driver mutation and with contraindications to angiogenesis inhibitors or candidates for redifferentiation therapy.
Authors
- Tommaso Porcelli (ORCID: https://orcid.org/0000-0002-6162-5819)
- Martin Schlumberger
- Mariantonia Nacchio (ORCID: https://orcid.org/0000-0002-8528-5273)
- Domenico Salvatore (ORCID: https://orcid.org/0000-0002-4556-7620)
- Anna Maria Cerbone
- Maria Angela De Stefano
- Cristina Luongo (ORCID: https://orcid.org/0000-0002-9127-4538)
- Carmine Di Luccio
Institutions
- Institut Gustave Roussy (FR)
- Schlumberger (France) (FR)
- University of Naples Federico II (IT)
Publication Details
- Journal
- European Thyroid Journal
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1530/etj-24-0332
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Università degli Studi di Napoli Federico II
- Associazione Italiana per la Ricerca sul Cancro